Verve Therapeutics
Biotechnology, 500 Technology Sq Ste 901, Boston, Massachusetts, 02139, United States, 201-500 Employees
Phone Number: 61********
Who is VERVE THERAPEUTICS
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular med...
Read More
-
Headquarters: 500 Technology Sq Ste 901, Boston, Massachusetts, 02139, United States
-
Date Founded: 2018
-
Employees: 201-500
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Sekar Kathiresan
Email
Phone
Industry: Biotechnology
SIC Code: 8062
Does something look wrong? Fix it. | View contact records from VERVE THERAPEUTICS
Verve Therapeutics Org Chart and Mapping
Similar Companies to Verve Therapeutics
Alnylam Pharmaceuticals
-
1001-5000
-
$ 500 Million to 1 Billion
Beam Therapeutics
-
501-1000
-
$ 50 Million to 100 Million
CRISPR Therapeutics
-
201-500
-
$ 100 Million to 250 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Verve Therapeutics
Answer: Verve Therapeutics's headquarters are located at 500 Technology Sq Ste 901, Boston, Massachusetts, 02139, United States
Answer: Verve Therapeutics's phone number is 61********
Answer: Verve Therapeutics's official website is https://vervetx.com
Answer: Verve Therapeutics's revenue is $10 Million to $25 Million
Answer: Verve Therapeutics's SIC: 8062
Answer: Verve Therapeutics has 201-500 employees
Answer: Verve Therapeutics is in Biotechnology
Answer: Verve Therapeutics top competitors include: Alnylam Pharmaceuticals , Beam Therapeutics , CRISPR Therapeutics
Answer: Verve Therapeutics contact info: Phone number: 61******** Website: https://vervetx.com
Answer: Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verves gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month